Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-a inhibitor

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-a inhibitor. | Biesen et al. Arthritis Research Therapy 2011 13 R26 http arthritis-research.eom content 13 1 R26 RESEARCH ARTICLE Open Access Anti-dsDNA-NcX ELISA dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus 1 2 2 1111 Robert Biesen Cornelia Dahnrich Anke Rosemann Fidan Barkhudarova Thomas Rose Olga Jakob Anne Bruns Marina Backhaus1 Winfried Stocker2 Gerd-Rudiger Burmester1 Wolfgang Schlumberger2 Karl Egerer1 and Falk Hiepe1 Abstract Introduction The objective of this study was to compare the clinical usefulness of the new anti-double-stranded DNA nucleosome-complexed enzyme-linked immunosorbent assay Anti-dsDNA-NcX ELISA which is based on dsDNA-loaded nucleosomes as antigens with established test systems based on dsDNA or nucleosomes alone for systemic lupus erythematosus SLE diagnostics and determination of disease activity. Methods Sera from a cohort of 964 individuals comprising 207 SLE patients 357 disease controls and 400 healthy donors were investigated using the Anti-dsDNA-NcX ELISA Farr assay Anti-dsDNA ELISA Anti-nucleosome ELISA and Crithidia luciliae immunofluorescence CLIF assay all of which are tests available from EUROIMMUN Medizinische Labordiagnostika AG Lubeck Germany . Receiver operating characteristic curve analyses were performed to compare the sensitivity and specificity of each assay. The test results yielded by these assays in a group of 165 fully characterized SLE patients were compared with the corresponding medical records. Results The Anti-dsDNA-NcX ELISA was found to have a sensitivity of 60.9 and a specificity of 98.9 in all 964 individuals at the manufacturer s cutoff of 100 U ml. At a comparable specificity of 99 the sensitivity amounted to 59.9 for the Anti-dsDNA-NcX ELISA 54.1 for the Farr assay 53.6 for the antinucleosome ELISA and 35.8 for the anti-dsDNA ELISA. The CLIF assay had a sensitivity of 28.0 and a specificity of 98.2 . The Anti-dsDNA-NcX ELISA correlated mostly with .